• Users Online: 231
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 4  |  Issue : 2  |  Page : 158-163

Immunological and biochemical parameters in patients with hepatitis C virus nephropathy before and after direct hepatitis C virus antiviral agents

Department of Internal Medicine and Nephrology, Faculty of Medicine, Assiut University, Assiut, Egypt

Correspondence Address:
Dr. Effat A. E. Tony
Professor of Internal Medicine and Nephrology, Faculty of Medicine, Assiut University, Assiut
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCMRP.JCMRP_91_18

Rights and Permissions

Background Chronic hepatitis C is associated with multiple extrahepatic manifestations that may affect the infected patients. Egypt is the country with the highest incidence of hepatitis C virus (HCV) infection in the world. Hepatitis C-induced kidney disease is a devastating complication in patients with HCV infection. The development of multiple direct-acting antivirals (DAAs) has revolutionized the HCV infection treatment. Aim The aim was to determine the changes in immunological and biochemical parameters in patients with HCV nephropathy who receive DAA. Patients and methods The study included 30 patients diagnosed with HCV nephropathy according to the inclusion criteria and were tested for the immunological (C3, C4, rheumatoid factor) and biochemical parameters (urea, creatinine, urine analysis, 24 h proteins), before receiving their direct HCV antiviral agents for 12 weeks. Then participants were followed up regarding their immunological and biochemical parameters directly after termination of treatment. Results A total of 18 (60%) patients received sofosbuvir and daclatasvir with ribavirin, whereas 12 (40%) patients were on ombitasvir, ritnoprevir, and paritaprevir with ribavirin. Levels of transaminases were significantly improved after direct HCV antiviral agents in the current study. Significant improvement in the mean levels of blood urea and creatinine after direct HCV antiviral agents post-therapy when compared with their levels before treatment (49.16 ± 15.52 and 285.11 ± 39.07 mg/dl at pretreatment versus 25.44 ± 9.37 and185.03 ± 31.07 mg/dl after treatment respectively, with P < 0.05) with significant reduction in 24-h urinary protein following the antiviral therapy. Our study showed significant improvement in C3 and C4 levels after therapy with DAA. After 12 weeks of the therapy, all patients had negative HCV RNA by PCR at follow-up. Conclusion HCV infection is a major medical burden in patients with chronic kidney disease. However, HCV infection itself can cause chronic kidney disease. Effective antiviral agents play an important role in improvement of HCV-related nephropathy and other extrahepatic manifestations.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded55    
    Comments [Add]    

Recommend this journal